Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of the Influence of Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Asundexian in Participants With Mild or Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function.

NCT05419635 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05419635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05419635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of the Influence of Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Asundexian in Participants With Mild or Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function.
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
June 14, 2022
Completion date
August 21, 2023
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction, atrial fibrillation, hepatic impairment, non-cardioembolic ischemic stroke, prevention of thromboembolic events